GSK Registers A Win For Older People RSV Vaccine – But Awaited Data Will Be Crucial

Prevention Rate Still Undisclosed

 
• By Andrew McConaghie
  
GSK_HQ
GSK is the first of the RSV vaccine competitors to declare a successful Phase III study, but the devil will be in the detail.

More from Clinical Trials

More from R&D